Mesothelioma Publication - Sv40 Specific Recall Immunity

This is an abstract of an article about malignant pleural mesothelioma and SV40 specific recall immunity that was published at PubMed by the NIH.

Jasani B, Coleman S, Butchart E, Evans EM, Adams M, Mason M, Gibbs A, Tabi Z.
Department of Pathology, Cardiff and Vale NHS Trust and School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.

Diffuse malignant pleural mesothelioma (MPM) is the third most common lung malignancy showing rising incidence with 250,000 deaths expected from it in Western Europe over the next 35 year. The tumour is generally resistant to conventional treatment and there is urgent need for novel preventative and therapeutic measures to combat this growing public threat. Finding of SV40 DNA sequences in a high proportion (40-90%) of several series of MPM cases, and suggestion of its potential co-carcinogen role provide a rationale for the development of novel anti-MPM vaccines incorporating SV40 gene sequences or antigenic determinants. As a prelude to adopting this approach, general T cell function was examined in relatively early cases of MPM presenting for biopsy or debulking surgery. CD8+ T cell responses were studied using antigenic epitopes of common viral antigens covering a broad range of haplotypes. 74.1% (20/27) of MPM patients and 80% (8/10) of the control subjects showed T cell responsiveness to the viral peptides mix, whilst a small proportion showed SV40 specific recall immunity.

Eexposure to asbestos is known to cause serious illnesses such as mesothelioma, asbestos-related lung cancer or asbestosis.